Calis Mustafa, Ates Filiz, Yazici Cevat, Kose Kader, Kirnap Mehmet, Demir Meltem, Borlu Murat, Evereklioglu Cem
Department of Physical Medicine and Rehabilitation, Erciyes University Medical Faculty, Kayseri, 38039, Turkey.
Rheumatol Int. 2005 Aug;25(6):452-6. doi: 10.1007/s00296-005-0612-z. Epub 2005 May 3.
Behçet's disease (BD) is a systemic vasculitis. Although its clinical characteristics are well defined, the etiology and immune pathogenesis are not clear yet. Neutrophilic vasculitis, which is a consequence of immunological events, is suggested as the underlying pathophysiological mechanism. Adenosine deaminase (ADA) is a non-specific marker of T-lymphocyte activation. A total of 75 patients with BD (45 women and 30 men) and 25 age-matched and gender-matched healthy control volunteers (13 women and 12 men) were included in this study. BD patients were divided into three groups according to their clinical findings: inactive BD patients (group 1, n=25); active BD patients under colchicine treatment (group 2, n=25); and active BD patients without colchicine treatment (group 3, n=25). Plasma ADA (p-ADA) levels of all BD patients and the control group were measured and compared. The relationship between p-ADA levels and disease activity, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels was evaluated and correlated. Patients with BD had significantly higher p-ADA levels (20.6+/-6.3 U/l) than control subjects (12.8+/-1.8 U/l; P<0.001). The p-ADA levels of patients with active BD were significantly (for each, P<0.05) higher than those of inactive BD patients or controls. On the other hand, the difference was not significant (P>0.05) between active patients with or without colchicine use. In addition, there were significantly positive correlations between p-ADA, ESR and CRP levels in patients with BD (for each, P<0.05). However, disease duration or haemoglobin levels were not relevant. ADA level may be a valuable and supportive indicator of disease activity and is not affected by colchicine therapy in BD.
白塞病(BD)是一种全身性血管炎。尽管其临床特征已明确界定,但其病因和免疫发病机制尚不清楚。免疫事件导致的嗜中性粒细胞性血管炎被认为是潜在的病理生理机制。腺苷脱氨酶(ADA)是T淋巴细胞活化的非特异性标志物。本研究纳入了75例BD患者(45例女性和30例男性)以及25例年龄和性别匹配的健康对照志愿者(13例女性和12例男性)。BD患者根据其临床症状分为三组:非活动期BD患者(第1组,n = 25);接受秋水仙碱治疗的活动期BD患者(第2组,n = 25);未接受秋水仙碱治疗的活动期BD患者(第3组,n = 25)。测量并比较了所有BD患者和对照组的血浆ADA(p - ADA)水平。评估并关联了p - ADA水平与疾病活动度、红细胞沉降率(ESR)和C反应蛋白(CRP)水平之间的关系。BD患者的p - ADA水平(20.6±6.3 U/l)显著高于对照组(12.8±1.8 U/l;P < 0.001)。活动期BD患者的p - ADA水平显著高于非活动期BD患者或对照组(每组P < 0.05)。另一方面,使用或未使用秋水仙碱的活动期患者之间差异不显著(P > 0.05)。此外,BD患者的p - ADA、ESR和CRP水平之间存在显著正相关(每组P < 0.05)。然而,病程或血红蛋白水平与之无关。ADA水平可能是疾病活动度的一个有价值的辅助指标,且在BD中不受秋水仙碱治疗的影响。